The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...

In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary ... 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and ...

Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $133.00.Don't ...

Jan. 6, 2025 — Protein aggregation is typical of various neurodegenerative diseases such as Alzheimer's, Parkinson's and prion diseases such as Creutzfeld-Jakob disease. A research team has now ...

Raise a glass? Not so fast—Alcohol may be speeding up your risk of getting Alzheimer’s.

Dec. 19, 2024 — Researchers have discovered a surprising link between a chronic gut infection caused by a common virus and the development of Alzheimer's disease in a subset of people.

University of Pittsburgh researchers uncovered a surprising link between Alzheimer's disease and herpes simplex virus-1 (HSV-1), suggesting that viral infections may play a role in the disease.